Teva Pharmaceutical Industries

Ultime notizie

Titoli nella lingua originale della fonte.

• Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome (si apre in una nuova scheda)

  Yahoo Finance UK · 2 ott 2026

• Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history (si apre in una nuova scheda)

  Yahoo Finance Australia · 1 ott 2026

• TD Cowen Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA) (si apre in una nuova scheda)

  MarketBeat · 1 ott 2026

• Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries’ (TEVA) Margin Expansion (si apre in una nuova scheda)

  Yahoo Finance · 1 ott 2026

• TD Cowen Initiates Teva Pharmaceutical Industries at Buy With $55 Price Target (si apre in una nuova scheda)

  Yahoo Finance · 1 ott 2026

• Teva Pharmaceutical and Samsung Bioepis Forge Global Biosimilar Partnership (TEVA) (si apre in una nuova scheda)

  GuruFocus · 1 ott 2026

• Samsung Bioepis, Teva expand biosimilar pact to target US and Europe - CHOSUNBIZ (si apre in una nuova scheda)

  Chosunbiz · 1 ott 2026

• Samsung Bioepis, Teva enter commercialization agreement on 6 biosimilar candidates (si apre in una nuova scheda)

  The Korea Times · 1 ott 2026

• Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History (si apre in una nuova scheda)

  Yahoo! Finance Canada · 1 ott 2026

• Teva names Serge Rogasik as CEO of API, CDMO business (si apre in una nuova scheda)

  TradingView · 30 set 2026

• Samsung Bioepis and Teva Expand Strategic Partn… | UNI India (si apre in una nuova scheda)

  uniindia.com · 30 set 2026

• Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Moderate Buy" from Analysts (si apre in una nuova scheda)

  MarketBeat · 30 set 2026

• Teva's Branded Drugs Take Center Stage in Its Growth Strategy (si apre in una nuova scheda)

  TradingView · 29 set 2026

• Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround (si apre in una nuova scheda)

  fool.com · 29 set 2026

• Teva Pharmaceutical Industries (NYSE:TEVA) Stock Forecast & Analyst Predictions (si apre in una nuova scheda)

  Simply Wall Street · 29 set 2026

• Teva Pharmaceutical Industries Gains FDA Nod for Degevma Biosimi (si apre in una nuova scheda)

  GuruFocus · 28 set 2026

• Form 4 TEVA PHARMACEUTICAL INDUSTRIES LTD For: 27 September By Investing.com (si apre in una nuova scheda)

  Investing.com Canada · 27 set 2026

• Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET (si apre in una nuova scheda)

  riauone.com · 24 set 2026

• Teva Pharmaceutical Industries stock trades 4.36 percent below its yearly high (si apre in una nuova scheda)

  AD HOC NEWS · 24 set 2026

• Teva releases Q3 2026 Aide Memoire ahead of November earnings (si apre in una nuova scheda)

  scanx.trade · 23 set 2026

• Teva Pharmaceutical Industries Ltd. to Report Third Quarter 2026 Financial Results on November 3, 2026 (si apre in una nuova scheda)

  Quiver Quantitative · 23 set 2026

• Third-quarter results are set for 7 a.m.; Teva's call follows at 8. (si apre in una nuova scheda)

  Stock Titan · 23 set 2026

• Teva Releases Q3 2026 Aide Memoire (si apre in una nuova scheda)

  GlobeNewswire · 23 set 2026

• Oppenheimer Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA) (si apre in una nuova scheda)

  MarketBeat · 23 set 2026

• Teva Eyes New Growth Phase After Securing Investment-Grade Ratings (si apre in una nuova scheda)

  TradingView · 23 set 2026

• Brian Savage Sells 7,342 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock (si apre in una nuova scheda)

  MarketBeat · 22 set 2026

• Teva Pharmaceutical Industries (NYSE:TEVA) Director Roberto Mignone Sells 367,600 Shares (si apre in una nuova scheda)

  MarketBeat · 22 set 2026

• Director’s fund exits Teva Pharmaceutical Industries (TEVA) stake in one-day sale (si apre in una nuova scheda)

  Stock Titan · 22 set 2026

• Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline (si apre in una nuova scheda)

  Yahoo Finance · 22 set 2026

• Teva (NYSE: TEVA) legal chief files $273K share-sale notice (si apre in una nuova scheda)

  Stock Titan · 21 set 2026